Immuneering (IMRX)

• Market cap: $52.9M
• 1 day: 1.38%
• 5 days: 5.00%
• 1 month: -3.29%
• 3 months: -23.04%
• 6 months: -25.76%
• Year to date: -33.48%
• 1 year: -0.68%
• 5 years: -91.64%
• 10 years: -91.64%
• Sector: Healthcare
• Industry: Biotechnology

About: Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Employees: 66

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

11% more funds holding

Funds holding: 38 [Q3] → 42 (+4) [Q4]

0.83% less ownership

Funds ownership: 14.69% [Q3] → 13.86% (-0.83%) [Q4]

14% less capital invested

Capital invested by funds: $10.9M [Q3] → $9.32M (-$1.55M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 716% upside
• Avg. target: $12.50 750% upside
• High target: $13 784% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Needham Ami Fadia 18% 1-year accuracy 29 / 160 met price target	716% upside $12	Buy Reiterated	10 Apr 2025
Chardan Capital Geulah Livshits 10% 1-year accuracy 6 / 59 met price target	784% upside $13	Buy Maintained	24 Mar 2025